Search clinical trials for: ADPM

Total 1262 results

Memorial Sloan Kettering Cancer Center

Completed

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma

United States
University of Michigan Rogel Cancer Center
AstraZeneca; Janssen Scientific Affairs, LLC

Active, not recruiting

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Sarcoma | Sarcoma Metastatic

United States
National Cancer Center Hospital East
Merck Sharp & Dohme LLC

Completed

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer (OLAPem)

Ovarian Cancer

Japan
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; Clovis Oncology, Inc.

Active, not recruiting

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Leiomyosarcoma

United States
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
Tesaro, Inc.
Gynecologic Oncology Group

Terminated

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)

Ovarian Neoplasms

United States
Saitama Medical University International Medical...
National Cancer Center, Japan; Tokyo University; Cancer Institute Hospital, Japan and other collaborators

Active, not recruiting

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Cervical Cancer

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Withdrawn

Study of M4344 in Combination With Niraparib

Breast Cancer | Advanced Solid Tumor
Seoul National University Hospital
AstraZeneca

Active, not recruiting

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Breast Neoplasms

Korea, Republic of
AbbVie (prior sponsor, Abbott)

Completed

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Brain Diseases | Central Nervous System Diseases | Neoplasm Metastasis | Brain Neoplasms | Nervous System Neoplasms

United States, Canada, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Breast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Colon Cancer | Solid Tumors

United States, Netherlands, Spain
Institut du Cancer de Montpellier - Val d'Aurelle

Terminated

A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (RAPIBE)

Brain Metastases

France
Institut Curie
AstraZeneca

Completed

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP)

Radiotherapy Side Effect | Breast Neoplasm Malignant Female | Breast Neoplasms, Triple-Negative

France
University Medical Centre Ljubljana

Recruiting

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients (CYPHER-TXPilot)

CMV Viremia

Slovenia
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (REVOCAN)

Ovarian Cancer

France
Shandong University
Sun Yat-sen University; Zai Lab (Shanghai) Co., Ltd.; Tongji Hospital; Women's...

Recruiting

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial Carcinoma | Serous Carcinoma

China
National University Hospital, Singapore

Recruiting

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies (MEDIPAC)

Solid Tumor, Adult

Singapore
University of Alabama at Birmingham
Tesaro, Inc.; Susan G. Komen Breast Cancer Foundation; Translational Breast Cancer... and other collaborators

Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Metastatic Breast Cancer | HER2 Positive Breast Carcinoma

United States
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
The Netherlands Cancer Institute

Active, not recruiting

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer (Subito)

Breast Cancer

Netherlands, France
AstraZeneca

Active, not recruiting

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) (BAYOU)

Urinary Bladder Neoplasms

United States, Spain, Canada, Taiwan, Vietnam, Korea, Republic of, Russian Federation
New Mexico Cancer Care Alliance

Active, not recruiting

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
The Clatterbridge Cancer Centre NHS Foundation...
University of Liverpool

Unknown

A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE)

Cervical Cancer

United Kingdom
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Ovarian Cancer | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Jishuitan Hospital

Recruiting

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma

Soft Tissue Sarcoma

China
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
Jean-Pierre Routy

Recruiting

Letermovir in ART-treated HIV-infected Persons (Letermovir)

People Living With HIV

Canada
California Pacific Medical Center Research Institute
M.D. Anderson Cancer Center

Recruiting

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Metastatic Melanoma

United States
Massachusetts General Hospital
Tesaro, Inc.

Recruiting

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Lung Cancer

United States
Georgetown University
Pfizer

Active, not recruiting

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Breast Cancer

United States
Georgetown University

Active, not recruiting

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Cholangiocarcinoma

United States
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Completed

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)

Epithelial Ovarian Cancer

Denmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
University Health Network, Toronto
AstraZeneca

Completed

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Ovarian Cancer

Canada
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

France, United Kingdom, Czechia, Korea, Republic of, Netherlands
AbbVie (prior sponsor, Abbott)

Completed

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

Brain Metastases From Non-small Cell Lung Cancer
Vejle Hospital
Abbott

Completed

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Ovarian Cancer

Denmark
Sanofi

No longer available

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Breast Cancer
AstraZeneca

Completed

Open Label, Dose Escalation Phase I Study of AZD2281

Advanced Solid Malignancies

Japan
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
Pfizer

Terminated

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Genes, BRCA 1

United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
Yale University

Completed

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Colorectal Cancer

United States
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Melanoma | Glioblastoma Multiforme | Recurrence of Solid Tumor

Search clinical trials for: ADPM

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations